147 related articles for article (PubMed ID: 11309319)
1. Inhibitors of histone deacetylase are potentially effective anticancer agents.
Marks PA; Rifkind RA; Richon VM; Breslow R
Clin Cancer Res; 2001 Apr; 7(4):759-60. PubMed ID: 11309319
[No Abstract] [Full Text] [Related]
2. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
3. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
4. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.
Witt O; Lindemann R
Cancer Lett; 2009 Aug; 280(2):123-4. PubMed ID: 19303208
[No Abstract] [Full Text] [Related]
7. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
9. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
13. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
15. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
16. [Histone deacetylase inhibitors--new anticancer agents?].
Yoshida M; Horinouchi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
[No Abstract] [Full Text] [Related]
17. [Histone deacetylase-targeted anti-leukemia therapy].
Ozawa Y
Rinsho Ketsueki; 2002 Apr; 43(4):231-4. PubMed ID: 12043197
[No Abstract] [Full Text] [Related]
18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
19. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]